

[Open Peer Review on Qeios](#)

Flavocillin: a potent TrxR and OATP inhibitor

Dimitris Labrou, Mustafa Pehlivan

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.

Abstract

Flavocillin, a newly discovered beta-lactam antibiotic, shows promise in its ability to be a TrxR inhibitor. Through our docking experiments, we identified key residues in the docking process, namely ALA295, GLN294, GLY41, GLY12, GLY36, GLY38, SER13, PRO15, ALA16, SER298 that prove the idea that this molecule can increase the susceptibility of various bacteria to beta-lactams, combined with this TrxR inhibitor. Moreover, HIV is known to thrive with the help of reduced oxidative stress. The opposite effect could minimize the viral copies, without the intervention of antiviral drugs.

Introduction

Beta lactams are a group of molecules that all share a common structure, that is the beta-lactam ring^[1], with the help of which, the molecule manages to bind to transpeptidase, a known component of the cell wall of bacteria and thus, inhibit peptidoglycan, causing disruption of the wall and the dismemberment of the cell due to extreme outer pressure from the environment.^[2] Beta lactams indicate various bacteria that are either aerobic/anaerobic or gram-positive/gram-negative. Each bacteria can build up a tolerance to the beta-lactams, by producing beta-lactamases, enzymes that break up the beta-lactam ring, thus disallowing the interaction between the drug and the transpeptidase.^[3] For this reason, scientists have developed beta-lactamase inhibitors, such as clavulanic acid and tazobactam.^[4]

Another way via which the bacterium can withstand the effects of drugs is through the NADPH system and specifically, through its derivatives, the thioredoxin reductase(TrxR) and the glutaredoxin reductase(GrxR). These molecules exist both in bacteria and human tissues, with some minor differences in sequencing. Bacteria can have one, or none of them.^[5] It has been proven that the inhibition of TrxR in E.coli tends to improve the efficacy profile of antibiotics.^[6] So the bigger question, is whether TrxR(or GrxR for that matter) is involved in the recruitment of beta-lactamases.

A recent discovery pointed out a new age in antibiotic production. This came with the discovery of flavocillin. Flavocillin is essentially a beta-lactam that carries a flavonone in its group, as an R substitute and has shown great affinity, in vitro, for various strains of bacteria. Apart from the beta-lactam ring, the R group might be essentially an active component, offering to adjust properties, the same as other flavonoids. This should be tested in human cells and bacteria.

Methods

Through our research, we performed docking experiments for flavocillin, with the help of the software mcule, against the TrxR of E.coli for the area (x,y,z)=(26.6282, 30.8226, -12.0442) and found an affinity of -10.1 (high) that allowed us to assume that potentially, this antibiotic has some anti-inflammatory properties and could be used for far more conditions than merely an antibiotic. In more detail, the most prevalent binding site was for ALA295, GLN294, GLY41, GLY12, GLY36, GLY38, SER13, PRO15, ALA16, and SER298. The R group of flavocillin offers this affinity, proving that it is an active ingredient. (figure 1)




Figure 1. Docking results for Flavocillin

Results

In Silico docking, models were obtained for Flavocillin by using ADMETSar version 2 software.^[7] According to these results, there were 0 violations of Lipinski's druggability rules.^[8] The Human Intestinal absorption value for Flavocillin was 0.6236 which can be categorized as "middle" intestinal absorption.^[9] (figure 2). Since the prediction of oral bioavailability score was around 0.78, Flavocillin is considered to have good oral bioavailability.^[10] In terms of drug safety profile prediction, Flavocillin is not an hERG inhibitor which would make it stronger as a new drug candidate because it will not enhance the risk of cardiovascular disease.^[11] In addition, Flavocillin was OATP1B1 and OATP1B3 inhibitor according to the same modeling with high inhibitory scores of 0,88 and 0,92 respectively. This indicated that Flavocillin would additionally have a similar mechanism of action to other OAPT inhibitors in the market which are already in clinical use against certain infectious diseases such as tuberculosis.

Discussion

Because of the slightly larger structure of a flavonone group as a subgroup of Flavonoids on the variable R group, Flavocillin can enhance or cause the eradication of bacterial biofilm formation. This way, Flavocillin may target bacterial biofilms also.^[12]

In Vitro, test results showed that Flavocillin targets mainly *S. Aureus* strains, MRSA, and *S. mutans*. *M. Catarrhalis* and was highly active on *C. Stiratum* when compared to Ampicillin and other antibiotics.^[13]

Organic anion-transporting polypeptides(OATPs) are transporters that are useful targets against infectious diseases.^[14] Flavocillin is one of the OATPB1/OATPB3 inhibitors. One of the uses of such inhibitors is against HIV, but research should not be limited only to the most notorious of infections, but also focus on other important diseases, such as tuberculosis.

The mechanism of action of OATPs is to carry xenobiotics, that has a molecular weight above 350 Da, such as natural products. It even extends to endogenous ligands, such as albumin.^[15] Flavocillin shows a binding affinity for the OATPs that is measured to be 0,8809 for OATP1B1 and 0,9296 for OATP1B3. According to such findings, it is estimated that it would be a useful agent against *Mycobacterium avium* complex, leprosy, and, as mentioned, tuberculosis. The drug itself, being of 464.50 molecular weight, might also inhibit its metabolism, through the inhibition of OATPs and thus increase its levels in the bloodstream, bypassing first-pass metabolism, as shown in the case of simvastatin. However, there is a chance for increased drug-drug interactions, in terms of pharmacokinetics and this should be studied further.^[16] Even more, the side effects would be potentially increased, causing a less tolerable safety profile.

Computational molecular modeling was performed for Flavocillin by using Protos and SEA search software. According to the obtained results, the drug safety profile of Flavocillin was high because the LD50 score was 5600 mg/kg and therefore high doses are required for Flavocillin to have toxic effects. On the other hand, SEA search results showed that Flavocillin is also a metallo beta-lactamase and beta-lactamase inhibitor. (figures 3 and 4)

For the tested Flavocillin Ammonium salt compound, in vitro test results concluded that Flavocillin antibiotics are effective on 10 types of bacteria including some of the antibiotic-resistant gram-positive and gram-negative bacteria and that they will be useful in the treatment of drug-resistant lung infections, pneumonia, hospital microbe, and septic bacteria. Among these, Flavocillin was the most effective against *Corynebacterium Stiratum* with a MIC value of 1, doing much better than Ampicillin and better than the combined effects of Amoxicillin and Clavulanic acid.

Flavocillin has a log P value of 2.7053 according to In Silico screening results. It obeys all 5 Lipinski rules such as a Molecular Weight of fewer than 500 daltons and no more than 5 proton donors and acceptors.

According to the results at Uppsala University, Department of Bacteriology, Flavocillin Ammonium salt is highly active against certain *Staphylococcus Aureus* strains and one strain of MRSA and cached some advantage in two strains over Ampicillin MIC values: EN1522 and EN1537.

According to the results at the Badebio lab of Eskişehir Anadolu University, Flavocillin Ammonium salts were highly active

against *S. mutans* (bacteria that cause oral infections), and against *C. Stiratum* and *M. catarrhalis* (two drug-resistant dangerous bacterial species which causes upper and lower respiratory tract infections, pneumonia, and sepsis). In terms of the activity of Flavocillin on *C. Stiratum*, it had an advantage over Ampicillin as Ampicillin is not active on *C. Stiratum* whereas Flavocillin's MIC value against *C. Stiratum* is excellent. A combination of antibiotics was studied in comparison to Flavocillin, and in certain cases, Flavocillin MIC values are better when compared to these comparative In Vitro studies, as evident from the table on page 3 of the formal report at Badebio lab, which summarizes MIC values of Flavocillin Bioactivity over various bacteria.^[13]

Conclusion

A clinical study needs to be performed to evaluate the safety profile of the drug. Despite this, the multiple affinities for various substrates beget that flavocillin might not be a too strong inhibitor of OATPs in lower dosages and the toxicodynamic profile is dose-dependent.

In Silico testing for the activity was also carried out for Flavocillin Ammonium salt. The results showed that Flavocillin acid-free form had a binding affinity of 0,8624 for OATP1B1 and 0,9328 for OATP1B3. According to these results, Flavocillin acid-free form had higher binding activity on OATP1B1 whereas Flavocillin ammonium salt had higher binding affinity on OATP1B3. It is expected that clinical studies in the future will fully determine the exact characteristics and suitability of Flavocillin derivatives as new drug candidates.

Property	Value
Molecular Weight	464.50
AlogP	2.71
H-Bond Acceptor	6
H-Bond Donor	2
Rotatable Bonds	4
Applicability Domain	In domain

ADMET predicted profile --- Classifications	Value	Probability
Human Intestinal Absorption	-	0.6237
Caco-2	-	0.7788
Blood Brain Barrier	-	0.9750
Human oral bioavailability	-	0.7857
Subcellular localization	Mitochondria	0.4607
OATP2B1 inhibitor	-	0.7264
OATP1B1 inhibitor	+	0.8809
OATP1B3 inhibitor	+	0.9296
MATE1 inhibitor	-	0.9600
OCT2 inhibitor	-	0.9425
BSEP inhibitor	+	0.8421
P-glycoprotein inhibitor	-	0.4719
P-glycoprotein substrate	+	0.5176
CYP3A4 substrate	+	0.6707
CYP2C9 substrate	-	1.0000
CYP2D6 substrate	-	0.8890
CYP3A4 inhibition	-	0.5894
CYP2C9 inhibition	-	0.7883

CYP2C19 inhibition	-	0.7715
CYP2D6 inhibition	-	0.8788
CYP1A2 inhibition	-	0.8052
CYP inhibitory promiscuity	-	0.8992
UGT catalyzed	-	0.0000
Carcinogenicity (binary)	-	0.7200
Carcinogenicity (trinary)	Non-required	0.6223
Eye corrosion	-	0.9891
Eye irritation	-	0.9600
Ames mutagenesis	-	0.6000
Human Ether-a-go-go-Related Gene inhibition	-	0.4702
Micronuclear	+	0.9100
Hepatotoxicity	+	0.6277
skin sensitisation	-	0.7909
Respiratory toxicity	+	0.9333
Reproductive toxicity	+	0.6444
Mitochondrial toxicity	+	0.9500
Nephrotoxicity	-	0.7207
Acute Oral Toxicity (c)	III	0.4790

Estrogen receptor binding	-	0.5384
Androgen receptor binding	+	0.5832
Thyroid receptor binding	-	0.5113
Glucocorticoid receptor binding	+	0.6058
Aromatase binding	-	0.5486
PPAR gamma	+	0.6936
Honey bee toxicity	-	0.7780
Biodegradation	-	0.9000
Crustacea aquatic toxicity	-	0.5400
Fish aquatic toxicity	+	0.9732

ADMET predicted profile --- Regressions	Value	Unit
Water solubility	-3.505	logS
Plasma protein binding	1.158	100%
Acute Oral Toxicity	1.375	log(1/(mol/kg))
Tetrahymena pyriformis	1.135	pIGC50 (ug/L)

Figure 2. ADMETSar version 2 based drug characteristics prediction In Silico for Flavocillin




Figure 3. In Silico Predicted LD50 of Flavocillin




Figure 4. SEA search server results for Flavocillin modelling

References

- ^{1.} [^] Ian C. Michelow, George H. McCracken, CHAPTER 248 - ANTIBACTERIAL THERAPEUTIC AGENTS, Editor(s): Ralph D. Feigin, James D. Cherry, Gail J. Demmler-Harrison, Sheldon L. Kaplan, Feigin and Cherry's Textbook of Pediatric Infectious Diseases (Sixth Edition), W.B. Saunders, 2009, Pages 3178-3227, ISBN 9781416040446, <https://doi.org/10.1016/B978-1-4160-4044-6.50253-3>.
- ^{2.} [^] Françoise van Bambeke, Marie-Paule Mingeot-Leclercq, Youri Glupczynski, Paul M. Tulkens, 137 - Mechanisms of Action, Editor(s): Jonathan Cohen, William G. Powderly, Steven M. Opal, Infectious Diseases (Fourth Edition), Elsevier, 2017, Pages 1162-1180.e1, ISBN 9780702062858, <https://doi.org/10.1016/B978-0-7020-6285-8.00137-4>.
- ^{3.} [^] John C. Christenson, E. Kent Korgenski, Ryan F. Relich, 286 - Laboratory Diagnosis of Infection Due to Bacteria, Fungi, Parasites, and Rickettsiae, Editor(s): Sarah S. Long, Charles G. Prober, Marc Fischer, Principles and Practice of Pediatric Infectious Diseases (Fifth Edition), Elsevier 2018, Pages 1422-1434.e3, ISBN 9780323401814, <https://doi.org/10.1016/B978-0-323-40181-4.00286-3>.
- ^{4.} [^] Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. β -Lactamases and β -Lactamase Inhibitors in the 21st Century. *J Mol Biol.* 2019 Aug 23;431(18):3472-3500. doi: 10.1016/j.jmb.2019.04.002. Epub 2019 Apr 5. PMID: 30959050; PMCID: PMC6723624.
- ^{5.} [^] Qi-An Sun, Vadim N. Gladyshev, [43] - Redox Regulation of Cell Signaling by Thioredoxin Reductases, Editor(s): Helmut Sies, Lester Packer, Methods in Enzymology, Academic Press, Volume 347, 2002, Pages 451-461, ISSN 0076-6879, ISBN 9780121822484, [https://doi.org/10.1016/S0076-6879\(02\)47045-0](https://doi.org/10.1016/S0076-6879(02)47045-0).
- ^{6.} [^] O'Loughlin J, Napolitano S, Alkhatami F, O'Beirne C, Marhöfer D, O'Shaughnessy M, Howe O, Tacke M, Rubini M. The Antibacterial Drug Candidate SBC3 is a Potent Inhibitor of Bacterial Thioredoxin Reductase. *ChemBiochem.* 2021 Mar 16;22(6):1093-1098. doi: 10.1002/cbic.202000707. Epub 2020 Dec 17. PMID: 33170522.
- ^{7.} [^] ADMETSar version 2 , <http://lmmd.ecust.edu.cn/admetsar2/result/?tid=596891>
- ^{8.} [^] Lipinski's rule of 5, <https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/lipinskis-rule-of-five>
- ^{9.} [^] Yan A, Wang Z, Cai Z. Prediction of human intestinal absorption by GA feature selection and support vector machine regression. *Int J Mol Sci.* 2008 Oct;9(10):1961-76. doi: 10.3390/ijms9101961. Epub 2008 Oct 20. PMID: 19325729; PMCID: PMC2635609.
- ^{10.} [^] CPMP, Note For Guidance On The Investigation of Bioavailability and Bioequivalence, London December 14 2000 , https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-investigation-bioavailability-bioequivalence_en.pdf
- ^{11.} [^] Lamothe SM, Guo J, Li W, Yang T, Zhang S. The Human Ether-a-go-go-related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage. *J Biol Chem.* 2016 Sep 23;291(39):20387-401. doi: 10.1074/jbc.M116.743138. Epub 2016 Aug 8. PMID: 27502273; PMCID: PMC5034037.
- ^{12.} [^] Verderosa AD, Totsika M, Fairfull-Smith KE. Bacterial Biofilm Eradication Agents: A Current Review. *Front Chem.*

2019 Nov 28;7:824. doi: 10.3389/fchem.2019.00824. PMID: 31850313; PMCID: PMC6893625.

13. ^{a, b} OFFICIAL BIOLOGICAL ACTIVITY REPORTS FOR FLAVOCILLIN AND FLAVOCILLIN AMMONIUM SALT CONFIRMING THE EFFECTIVENESS OF FLAVOCILLIN ANTIBIOTICS ON MRSA, *S. AUREUS*, *E. FAECALIS*, *E. FAECIUM*, *M. CATARRHALIS*, *S. MUTANS*, *E. HIRAE*, *S. MUTANS*, *C. STIRATUM* AND *S. EPIDERMIDIS*, Researchgate , November 2022 DOI: 10.13140/RG.2.2.32444.72325
14. [^] Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. *Br J Pharmacol.* 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25. PMID: 19785645; PMCID: PMC2765590.
15. [^] Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. *Xenobiotica.* 2008 Jul;38(7-8):778-801. doi: 10.1080/00498250801986951. PMID: 18668430.
16. [^] Krishna R, Garg A, Jin B, Keshavarz SS, Bieberdorf FA, Chodakewitz J, Wagner JA. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. *Br J Clin Pharmacol.* 2009 May;67(5):520-6. doi: 10.1111/j.1365-2125.2009.03385.x. Epub 2009 Feb 4. PMID: 19552746; PMCID: PMC2686068.